PAVmed Company Leadership
PAVM Stock | USD 0.77 0.01 1.32% |
PAVmed's insiders are aggressively buying. The analysis of insiders' sentiment of trading PAVmed Inc stock suggests that most insiders are extremely bullish at this time. PAVmed employs about 107 people. The company is managed by 10 executives with a total tenure of roughly 250 years, averaging almost 25.0 years of service per executive, having 10.7 employees per reported executive.
Insider Sentiment 100
Aggressively Buying
Selling | Buying |
Latest Trades
2022-12-07 | Michael J Glennon | Acquired 6666 @ 9.3 | View | ||
2022-12-05 | Michael J Glennon | Acquired 4133 @ 10.35 | View |
Monitoring PAVmed's insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
PAVmed |
PAVmed Management Team Effectiveness
The company has return on total asset (ROA) of (0.9591) % which means that it has lost $0.9591 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (13.5806) %, meaning that it created substantial loss on money invested by shareholders. PAVmed's management efficiency ratios could be used to measure how well PAVmed manages its routine affairs as well as how well it operates its assets and liabilities. As of the 19th of March 2025, Return On Equity is likely to grow to 2.44, while Return On Tangible Assets are likely to drop (1.91). At this time, PAVmed's Non Current Assets Total are very stable compared to the past year. As of the 19th of March 2025, Non Currrent Assets Other is likely to grow to about 1.4 M, though Net Tangible Assets are likely to grow to (17.3 M).As of the 19th of March 2025, Common Stock Shares Outstanding is likely to grow to about 6.9 M, though Net Loss is likely to grow to (76.3 M).
PAVmed Workforce Comparison
PAVmed Inc is rated below average in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 3,906. PAVmed holds roughly 107 in number of employees claiming about 2.74% of equities under Health Care industry.
The company has Profit Margin (PM) of 6.03 %, which can signify that it executes well on its competitive strategies and has good control over its expenditures. This is very large. Similarly, it shows Operating Margin (OM) of (11.62) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $11.62. PAVmed Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific PAVmed insiders, such as employees or executives, is commonly permitted as long as it does not rely on PAVmed's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, PAVmed insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Tasso Partners, Llc few days ago Insider Trading | ||
Deguzman Brian J. over a week ago Acquisition by Deguzman Brian J. of 50000 shares of PAVmed at 1.59 subject to Rule 16b-3 | ||
Aklog Lishan over two months ago Disposition of 12450 shares by Aklog Lishan of PAVmed at 1.6 subject to Rule 16b-3 | ||
Battleman David S. over three months ago Acquisition by Battleman David S. of 200000 shares of PAVmed at 1.0 subject to Rule 16b-3 | ||
Agrawal Sundeep over three months ago Acquisition by Agrawal Sundeep of 50000 shares of PAVmed at 1.04 subject to Rule 16b-3 | ||
Sirovich Matthew over three months ago Discretionary transaction by Sirovich Matthew of tradable shares of PAVmed subject to Rule 16b-3 | ||
Agrawal Sundeep over six months ago Acquisition by Agrawal Sundeep of 205000 shares of PAVmed at 1.63 subject to Rule 16b-3 | ||
Sparks Ronald M over six months ago Acquisition by Sparks Ronald M of 65000 shares of PAVmed subject to Rule 16b-3 |
PAVmed Notable Stakeholders
A PAVmed stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as PAVmed often face trade-offs trying to please all of them. PAVmed's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting PAVmed's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Dennis CPA | CFO President | Profile | |
Shaun MBA | Executive COO | Profile | |
Michael Gordon | General VP | Profile | |
Deepika Lakhani | Chief VP | Profile | |
Lishan MD | Chairman CEO | Profile | |
Michael Parks | Vice Relations | Profile | |
Adrian Miller | VP Relations | Profile | |
Brian MD | Chief Affairs | Profile | |
Victoria Lee | Senior Officer | Profile | |
Victoria MD | Senior Officer | Profile |
About PAVmed Management Performance
The success or failure of an entity such as PAVmed Inc often depends on how effective the management is. PAVmed management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of PAVmed management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the PAVmed management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (1.82) | (1.91) | |
Return On Capital Employed | 2.94 | 2.79 | |
Return On Assets | (1.74) | (1.83) | |
Return On Equity | 1.37 | 2.44 |
PAVmed Workforce Analysis
Traditionally, organizations such as PAVmed use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare PAVmed within its industry.PAVmed Manpower Efficiency
Return on PAVmed Manpower
Revenue Per Employee | 22.9K | |
Revenue Per Executive | 245.2K | |
Net Loss Per Employee | 599.8K | |
Net Loss Per Executive | 6.4M |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in PAVmed Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of PAVmed. If investors know PAVmed will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about PAVmed listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.14) | Revenue Per Share | Quarterly Revenue Growth 0.259 | Return On Assets | Return On Equity |
The market value of PAVmed Inc is measured differently than its book value, which is the value of PAVmed that is recorded on the company's balance sheet. Investors also form their own opinion of PAVmed's value that differs from its market value or its book value, called intrinsic value, which is PAVmed's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because PAVmed's market value can be influenced by many factors that don't directly affect PAVmed's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between PAVmed's value and its price as these two are different measures arrived at by different means. Investors typically determine if PAVmed is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, PAVmed's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.